The free fatty acid receptor 1 (FFA1), a G protein-coupled receptor (GPCR) naturally activated by long-chain fatty acids is a novel target for the treatment of metabolic diseases. The basic amine spirocyclic periphery of Eli Lilly's drug candidate LY2881835 for treatment of type 2 diabetes mellitus (which reached phase I clinical trials) inspired a series of novel FFA1 agonists containing the 3-[4-(benzyloxy)phenyl]propanoic acid pharmacophore core decorated with a range of spirocyclic motifs. The latter were prepared via the Prins cyclization and subsequent modification of the 4-hydroxytetrahydropyran moiety in the Prins product. Here, we synthesize 19 compounds and test for FFA1 activity. Within this pilot set, a nanomolar potency (EC 50 = 55 nM) was achieved.
Introduction
The free fatty acid receptor 1 (FFA1, known as GPR40 prior to its de-orphaning in 2003) promptly became a biological target of high importance from the standpoint of developing fundamentally new therapeutic agents against type 2 diabetes mellitus (T2DM). FFA1 agonists are capable of raising insulin levels but only do so in hyperglycemic state when the FFA1 expression is upregulated. 1 The activation of FFA1 triggers a GPCR signaling cascade which invokes insulin secretion to normalize blood glucose levels. As a result, the expression of the receptor goes back to normal, desensitizing the insulin-producing machinery to FFA1 agonists still remaining in circulation. 2 This is in sharp contrast to other antidiabetic agents, such as sulfonylureas, that continue stimulating insulin release irrespective of the current glucose levels and can, therefore, cause hypoglycemia (an adverse, potentially deadly condition).
The extensive worldwide research efforts in the decade following FFA1 de-orphaning aimed at developing clinically useful FFA1 agonists 3 were nearly halted after Takeda's first-in-class agent fasiglifam (TAK-875) was discontinued in phase III of human trials. 4 On the date of submission of this manuscript, only one FFA1 agonist (Piramal's compound P11187 of undisclosed structure) was in clinical research. 5 This is rather unfortunate as the efficacy profile of TAK-875, despite its idiosyncratic liver toxicity, was very good. 6 Therefore, if the toxicity profile of FFA1 agonists is diligently tackled, there remains an opportunity to bring the first drug in this class to market. 7 The toxicity of TAK-875 was debatably linked to its overly high lipophilicity. 7 On the one hand, relatively high lipophilicity is likely a pre-requisite for ligand's affinity to the receptor (considering the fact that its endogenous ligands are medium-to-long chain fatty acids 1 ). On the other hand increasing the polarity (i. e. increasing the total polar surface area or lowering the LogP) of FFA1 agonists could provide the solution to the toxicity problem. Recently, we reported potent and selective FFA1 agonists based on containing 1,3-oxazole, 1,2,4-oxadiazole 8 and 1,2,4-thiadiazole 9-10 grafted onto or replacing the phenyl ring of the 3- [4-(benzyloxy) phenyl]propanoic acid core, which mimics the fatty acid endogenous ligands of the receptor and is present in TAK-875 and other advanced compounds of this class (such as Amgen's AMG-837, 11 and Eli Lilly's Besides the heterocyclic appendage 8 or scaffold hopping [9] [10] approach realized in our previous studies, we became intrigued by the structure of LY2881835 and the presence of a basic amine center, in combination with the spirocyclic motif, in its periphery. Both aspects appeared quite appealing from the drug design standpoint. The basic center, which would likely be protonated at physiological pH, is capable of increasing hydrophilic character of LY2881835 itself or any related compounds. This was clearly a reassuring observation as high lipophilicity has been dogmatized as a pre-requisite to high ligand affinity toward FFA1 (we observed a significant activity drop on replacing the 3-phenylpropionic acid FFA1 pharmacophore with its more polar 1,3,4-thiadiazole congener 9 ). Spirocyclic moieties are considered privileged moieties in GPCR ligand design due to their pronounced three-dimensional character, which ensures better complementarity of a smallmolecule ligand to its protein target and, as a result, fewer off-target effects. 11 The Prins cyclization involving cyclic ketones and homoallylic alcohol under Lewis or Brønsted acid catalysis provides a facile entry into spirocyclic motifs which contain a potentially reactive functionality originating from the interception of intermediate spirocyclic carbocation with various nucleophiles (thus resulting in a formal three-component process). 12 Azacycloalkanones have been rarely employed as carbonyl components in the Prins cyclization, except for a comprehensive methodology report from the Ghosh group. 13 Recently, we described a facile and convenient protocol to prepare spirocyclic amino alcohol building blocks from a range of azacycloalkanones. 14 In particular, N-Boc-protected 1-oxa-9-azaspiro[5.5]undecan-4-ol (1) which was amenable by this method on a multigram scale, was viewed as a particularly valuable building block to graft diverse spirocyclic periphery, similar to that of LY2881835, onto the 3-[4-(benzyloxy)phenyl]propanoic acid core, which common to many advanced FFA1 agonists (vide supra), via a reductive amination of aldehyde building block 2 with a range of amines 3 derived from 1.
While 2 was lacking a substituent in position 3 of 3-phenylpropanoic carboxylate (which is present in many advanced compounds shown in Figure 1 ), we reasoned that the use of the simplified pharmacophore would allow streamlined screening for the optimal spirocyclic periphery in series 4.
Once lead compounds are identified within the latter, appropriate substitutions in the 3- [4- (benzyloxy)phenyl]propanoic acid portion of the future new agonists can be defined and introduced ( Figure 2 ). Herein, we describe the initial promising results related to the synthesis, biological and ADMET/PK profiling of compounds belonging to series 4.
Figure 2.
Design and retrosynthetic analysis of new series of FFA1 agonists 4.
Results and discussion
The synthesis of core aldehyde building block 2 commenced with known 15 aldehyde 5. The Horner- It should be noted that, owing to difficulties we faced in purification of the hydrochloride products, which required repeated manipulation of semi-purified material, the isolated yields of compounds 4a-s achieved in this study were relatively low (see ESI). Nonetheless, the synthetic strategy described above allowed the preparation of the required quantities of compounds 4a-s for the initial in vitro biological profiling of the lead compounds thus identifiedfor in vitro ADME and in vivo PK characterization. Further optimization of the synthesis of the frontrunner compounds will be needed before further development of the series disclosed herein.
Potential FFA1 agonists 4a-s thus synthesized were tested for FFA1 activation using calcium flux assay employing Chinese hamster ovary (CHO) cells engineered to stably express human FFA1. All compounds were tested in dose-response (% FFA1 activation) mode in order to determined EC 50 values. The latter, as well as % of maximum efficacy achieved for active compounds relative to reference agonist GW9508 16 (used at 5 M concentration throughout the study) are given in Table   1 . On examination of the FFA1 activation data presented in Table 1 it becomes clear that in the newly designed series, increased lipophilicity (in combination with the basic nitrogen center counterbalancing the lipophilic periphery) is the principal driver of potency, as it was described for FFA1
agonists in a number of instances. 10, 17 This should be expected for receptors modulated by endogenous free fatty acids and for the ligands intended to mimic the lipophilic character of the latter. Indeed, the hydrophilicity imparted by unsubstituted 1-oxa-9-azaspiro[5.5]undecane periphery (compound 4s) was detrimental to the agonistic potency. However, introduction of alkoxy substituents of increasing size (compound 4a-g) gradually brought the potency back into lowmicromolar range. Of particular interest is the influence of alkyl substituents in the pyran portion of the new FFA1 agonist scaffold of the potency (exemplified by compounds 4h-o). Here, introduction of lipohilic benzyl periphery results in a significant potency increase, with the most compound (4l) having EC 50 comparable to that of Takeda's phase III compound TAK-875 (EC 50 = 0.014 M). 18 Taking into account the size of the pilot set of compounds studied in this work, this attests to the success of the initial FFA1 design idea implemented in the new molecular scaffold.
We next determined the selectivity profile of the most potent GPR40 agonists (4k-n) against other free fatty acid receptors (FFA3/GPR41, FFA2/GPR43 and FFA4/GPR120). FFA2 and FFA3
agonists have a preference in binding short-chain fatty acids while FFA1 and FFA4 have a higher affinity to medium-and long-chain fatty acids. 19, 20 As it is seen from the activity data against this panel of GPCRs, the four lead compounds displayed high selectivity for FFA1 ( Table 2 ). In order to better understand the dramatic influence of the benzyl substituent in the 1-oxa-9azaspiro[5.5]undecane portion of the compounds (compared to the unsubstituted derivative), we have docked 4l and 4s in the FFA1 binding site ( Figure 3 ). Both compounds occupy similar positions within the binding cativy, forming the critical hydrogen bonds with R183 5.39 , R258 7.35 , Y91 3.37 and Y240 6.51 . The propanoic acid moeity may be further stabilized by a network of π-π interactions that could occur between F88 3.34 , F142 4.61 , W174 EL2 and F87 3.33 of the receptor and the aromatic rings of each compound. However, there are signifigant differences in the positioning of the spiro-pyran moiety, which is likely responsible for the observed differences in the potency of 4l (EC 50 = 0.055 M) and 4s (EC 50 >20.00 M). In 4s, this moiety positions toward the extracellular side while, in contrast, the potent 4l adopts a position, where 1oxa-9-azaspiro[5.5]undecane faces toward the intercelluar side ( Figure 3A) . Here, the terminal benzyl substituent positions within a favorable hydrophobic cavity forming numerous hydrophobic interactioins with L54 2.51 , L135 4.54 and V81 3.27 ,, while also having π-π stacking interactions with W131 4.50 ( Figure 3B ). Together these contacts drive the benzyl-substituted 1-oxa-9azaspiro[5.5]undecane moiety deep into the phosopholipid bilayer, which might be benefical for agonist activity. Figure 4A ). The position of 4s within the binding cavity is seemlingly tolerable, however, the ligand stablity is likely compromised by the electrostatic interactions between the positively charged amonium of its spyrio-pyran motif and the negatively charged phospholipid head. Here, the fluidity of the lipid bi-layer coupled with these strong electrostatic interactions may destabalise the binding conformation, which likely attributes to the low activity of the compound. In contrast, the benzyl substituent of compound 4l favors the more hydrophobic environment ( Figure 4B ), positioning at the interface between the lipid tails and protein which negates the detrimental attraction between the phostphate heads and positively charged amonium.
Since we were able to reach well into submicromolar potency range with our pilot set of 19 compounds (4a-s), we were also keen on assessing the preliminary ADME profile of the most active compounds from this set (4k-n). On examination of the data presented in Table 3 , several general observations can be made. All four compounds displayed satisfactory aqueous solubility and Caco-2 permeability, which confirmed the new chemotype was promising from further development prospective. The relatively high plasma protein binding observed for 4k-n perhaps is not surprising for these highly lipophilic compounds 22 and may not present a significant development obstacle provided the rate of dissociation from plasma proteins is sufficient to maintain the required plasma levels (vide infra). The principal weakness of the series studied herein was its low metabolic stability determined by incubation of compounds 4k-n in the presence of mouse liver microsomes. Indeed the half-life of 4l-m was around 10 minutes with unacceptably high clearance. a Each value is an average of n = 4, measured at c = 1 M. b Each value is an average of n = 2, measured at c = 10 M.
The highest metabolic stability observed for compound 4k (EC 50 = 0.41 M corresponding to 218 ng/mL) among the four selected frontrunner candidates was the principal decisive point in nominating this compounds for pharmacokinetic characterization in mice at the dosage of 10 mg/kg (administered intravenously and orally).
As can be seen from pharmacokinetic parameters presented in Table 4 , compound 4k demonstrated satisfactory oral bioavailability (F, %) and plasma levels commensurate with or significantly higher than the in vitro EC 50 value, on oral and intravenous administration, respectively. 
Conclusions
The toxicity associated with high lipophilicity of previous FFA1 agonists has been a limiting factor in the progression through clinical trials. Here, we have reported on a novel series of FFA1 
Experimental section

General experimental
All reactions were conducted in oven-dried glassware in atmosphere of nitrogen. Melting points
were measured with a Buchi В-520 melting point apparatus and were not corrected. Analytical thinlayer chromatography was carried out on Silufol UV-254 silica gel plates using appropriate mixtures of ethyl acetate and hexane. Compounds were visualized with short-wavelength UV light. 1 H NMR and 13 C NMR spectra were recorded on Bruker MSL-300 spectrometers in DMSO-D6-d 6
using TMS as an internal standard. Mass spectra were recorded using Shimadzu LCMS-2020 system with electron-spray (ESI) ionization. All and reagents and solvents were obtained from commercial sources and used without purification.
All mass-spectroscopic measurements required for determination of ADME properties were performed using Shimadzu VP HPLC system including vacuum degasser, gradient pumps, reverse phase HPLC column, column oven and autosampler. The HPLC system was coupled with tandem mass spectrometer API 3000 (PE Sciex). The TurboIonSpray ion source was used in both positive and negative ion modes. Acquisition and analysis of the data were performed using Analyst 1.5.2 software (PE Sciex).
Synthetic organic chemistry
Starting materials
Boc-protected 1-oxa-9-azaspiro[5.5]undecan-4-ol (1) was synthesized as described previously. 14 (12) is a commercially available compound which can, alternatively, be prepared by deprotection of its N-Boc version reported earlier. 14 Aldehyde 5 is a known compound prepared according to the literature protocol. 15
Methyl 4-({4-[(1E)-3-tert-butoxy-3-oxoprop-1-en-1-yl]phenoxy}methyl)benzoate (7).
A 500-mL round-bottomed flask was charged with a suspension of NaH (60% dispersion in mineral oil, 1.1 g, 28 mmol) in dry THF (250 mL) and cooled to 0 °C. Phosphonate 6 (7.6 g, 30 mmol) was added in portions and the resulting mixture was stirred at that temperature for 1 h. A solution of compound 5 (6.7 g, 25 mmol) in THF (50 mL) was added dropwise. The reaction mixture was heated at reflux for 30 min, cooled down to r. t. and poured into water (250 mL). The aqueous solution was extracted with ethyl acetate (3 x 100 mL) and the combined organic extracts were washed with 5% aqueous HCl, 10% aqueous potassium bicarbonate, water, dried over anhydrous Na 2 SO 4 , filtered and concentrated in vacuo. The residue was purified by column chromatography on silica gel using 015% ethyl acetate in hexanes as eluent to provide the title compound. 8, 166.6, 159.9, 143.0, 141.7, 129.9, 129.6, 127.9, 127.0, 118.1, 115.1, 80.3, 69.4, 52.2, 28.2; MS m/z 369.6 (M + H + ).
Methyl 4-{[4-(3-tert-butoxy-3-oxopropyl)phenoxy]methyl}benzoate (8).
A 500-mL autoclave chamber was charged with a solution of compound 7 (7.7 g, 21 mmol) anhydrous methanol (250 mL) and Raney Ni (10 g, freshly prepared suspension). A 100-atm pressure of hydrogen was applied and the mixture was stirred at r. t. for 10 h. Upon release of the hydrogen pressure and purging with nitrogen, the contents of the autoclave were filtered through a pad of celite, washed with methanol and the filtrate was concentrated in vacuo to provide the title compound. 3, 166.9, 156.9, 142.4, 133.5, 129.9, 129.6, 129.4, 127.0, 114.8, 80.3, 69.4, 52.2, 37.3, 30.3, 28. 1; MS m/z 371.5 (M + H + ).
4-{[4-(3-Tert-butoxy-3-oxopropyl)phenoxy]methyl}benzoic acid (9).
A 25-mL round-bottomed flask was charged with a solution of compound 8 ( δ 172. 4, 171.8, 156.8 143.5, 133.5, 130.5, 129.4, 128.7, 127.0, 114.8, 80.4, 69.3, 37.3, 30.3, 28.1; MS m/z 357.6 (M + H + ).
Tert-butyl 3-{4-[(4-formylbenzyl)oxy]phenyl}propanoate (1).
A 250-mL three-necked round-bottomed flask kept under a positive pressure of nitrogen was charged with a solution of compound 9 (5.3 g, 15 mmol, obtained from several runs of the previous three steps) in anhydrous THF (100 mL) and N-methylmorpholine (1.7 g, 17 mmol 13 C NMR (75 MHz, DMSO-d 6 ) δ 206. 8, 154.8, 79.6, 74.9, 60.4, 52.7, 41.7, 39.1, 34.4, 28.4 To a 0 ºC, vigorously stirred suspension of NaH (6.54 g, 163 mmol, 60% dispersion in mineral oil)
in THF (300 mL) thriethylphosphonoacetate (45 g, 200 mmol) was added dropwise under argon.
The stirring continued at that temperature for 1 h, whereupon a solution of 10 (40 g, 149 mmol) in THF (100 mL) was added. The reaction mixture was allowed to reach r. t. and was stirred at that temperature for 18 h. The reaction mixture was poured into water (500 mL) and the aqueous phase was extracted with ethyl acetate (3 x 200 mL 2, 153.9, 78.4, 69.7, 59.7, 41.6, 41.1, 38.6, 32.0, 28.7, 28.1, 26.8 . MS m/z 314.5 (M+H + ).
General procedure for the preparation of compounds 3a-g.
A solution of tert-butyl 1-oxa-9-azaspiro[5.5]undecan- 4-ol (4g, 14.8 mmol) in DMF (20 mL 1, 58.3, 54.8, 40.4, 38.8, 33.5, 31.3, 28. 0. MS m/z 185.9 (M+H + ).
4-Ethoxy-1-oxa-9-azaspiro[5.5]undecane hydrochloride (3b).
Yield 991 mg (63%). White crystals, m. p. = 191 -193 MS m/z 226.3 (M+H + ).
4-[(3-Fluorobenzyl)oxy]-1-oxa-9-azaspiro[5.5]undecane (3d).
This compound was converted to free base by partitioning between sat. aq. NaHCO 3 
4-(Benzyloxy)-1-oxa-9-azaspiro[5.5]undecane (3f).
General procedure for the preparation of compounds 3h-o.
n-BuLi (2.5M in hexane, 4 mL, 10.0 mmol) was added dropwise under argon to a 0 ºC suspension of the respective alkylphosphonium chloride (10.0 mmol) in THF (50 mL). The mixture was stirred for 30 min whereupon a solution of 10 (2.42 g, 9.0 mmol) in THF (10 mL) was added. The reaction mixture was allowed to warn up to r. t. and stirred at that temperature for 18 h. At that point, sat. aq. NH 4 Cl (25 mL) was added and the mixture was diluted with ethyl acetate (50 mL) and water (20 mL). Organic phase was separated and the aqueous phase was additionally extracted with ethyl acetate (2 x 50 mL). The combined organic extracts were washed with brine, dried over anhydrous Na 2 SO 4 , filtered and concentrated in vacuo. The residue was fractionated on silica gel using 05% ethyl acetate in hexanes as eluent. Fractions containing the olefination product (according to LC MS analysis) were pooled and concentrated to dryness. The material thus obtained was used in the subsequent steps without further purification.
To a solution of this material in EtOH (20 mL/mmol assuming 100% purity of the product in the previous step) HCOONH 4 (4 mmol/mmol) and 10% Pd on carbon (37 mg/mmol) were added and the resulting mixture was heated at reflux for 12 h. The mixture was cooled to r. t. and filtered through a plug of Celite (subsequently washing the latter with EtOH). The combined filtrate and washings were concentrate to dryness. The residue was partitioned between water (50 mL) and ethyl acetate (50 mL). The organic layer was separated and the aqueous layer was additionally extracted with ethyl acetate (2 x 50 mL). The combined organic extracts were washed with 3% aqueous citric acid, 5% aqueous NaHCO 3 and brine, dried over anhydrous Na 2 SO 4 , filtered and concentrated in vacuo. Without further purification, the residue was dissolved in CH 2 Cl 2 (3 mL/mmol calculated assuming 100% purity of the material obtained in the previous step), the solution was cooled to 0 ºC and TFA (1 mL/mmol) was added. The mixture thus obtained was stirred at 0 ºC for 6 h and then concentrated to dryness to provide, after crystallization from isopropyl alcohol, the target spirocyclic piperidine as a trifluoroacetate salt. Compounds 3h, 3j, 3mn were converted to hydrochloride salts by treatment of their r. t. solutions in 1,4-dioxane with 4M
HCl in 1,4-dioxane followed by stirring for 3 h, evaporation of the volatiles in vacuo and crystallization from isopropyl alcohol.
4-Methyl-1-oxa-9-azaspiro[5.5]undecane hydrochloride (3h).
Yield 342 mg (45% 2, 43.8, 35.2, 34.1, 25.4, 24.3, 22.3 . MS m/z 170.0 (M+H + ).
4-[4-(Trifluoromethyl)benzyl]-1-oxa-9-azaspiro[5.5]undecane trifluoroacetate (3i).
Yield 1 g (38%). Hygroscopic solid. 1 02 (m, 7H ). 13 C NMR (75 MHz, DMSO-d 6 ) δ 144. 8, 129.8, 126.7 (q, J = 31.6 Hz), 125.0 (q, J = 3.81 Hz), 122.6, 79.2, 68.1, 60.0, 42.2, 41.7, 35.3, 31.7, 31.1, 25.5 . MS m/z 314.0 (M+H + ).
4-(3-Fluorobenzyl)-1-oxa-9-azaspiro[5.5]undecane hydrochloride (3j)
Yield 1.03 g (65%). Hygroscopic solid. 1 2, 115.6 (d, J = 20.5 Hz), 112.7 (d, J = 20.7 Hz), 68.1, 60.0, 42.2, 41.8, 35.3, 31.7, 31.0, 25.5 . MS m/z 264.6 (M+H + ).
4-(4-Fluorobenzyl)-1-oxa-9-azaspiro[5.5]undecane trifluoroacetate (3k)
Yield 1, 41.8, 41.8, 35.4, 31.8, 31.4, 25.6 . MS m/z 264.1 (M+H + ). 7, 129.0, 128.2, 125.9, 68.1, 60.1, 42.7, 41.9, 35.4, 31.9, 31.3, 25.5 . MS m/z 246.2 (M+H + ).
4-Benzyl
4-(4-Methoxybenzyl)-1-oxa-9-azaspiro[5.5]undecane-9 hydrochloride (3m)
Yield 660 4, 131.4, 129.8, 113.5, 68.1, 60.0, 54.8, 41.7, 38.8, 38.7, 35.1, 31.9, 31.3, 25.2. MS m/z 275.8 (M+H + ). 2.3.7. 4-(4-Methylbenzyl) 4, 134.6, 128.7, 128.6, 68.1, 60.0, 42.2, 41.8, 38.8, 35.1, 31.9, 31.2, 25.3, 20.5 . MS m/z 260.5 (M+H + ). 2.3.8. 4-(2-fluorobenzyl)-1-oxa-9-azaspiro 1, 60.0, 41.8, 35.5, 35.3, 31.8, 30.4, 25.5 . MS m/z 263.9 (M+H + ).
4.
General procedure for the preparation of compounds 3p-r.
Isobutyl chloroformate (0.44 g, 3.19 mmol) was added dropwise under argon to a -30 ºC solution of 11 (1g, 3.19 mmol) and N-methylmorpholine (0.39 g, 3.83 mmol) in THF (40 mL). After a brief (30 min) stirring, a solution of the respective amidoxime (3.83 mmol) in THF (10 mL) was added dropwise. The reaction mixture was allowed to reach r. t., stirred at that temperature for 12 h, filtered and concentrated in vacuo. The residue was dissolved in toluene (50 mL), TBAF (0.1 g) was added and the mixture was heated at reflux for 5 h with azeotropic removal of water using a
Dean-Stark trap. The toluene solution was washed with water, 1% aqueous citric acid, 5% sat.
aqueous NaHCO 3 , brine, dried over anhydrous Na 2 SO 4 , filtered and concentrated to dryness in vacuo. The residue was fractionated on silica gel using chloroform as eluent. The fractions containing the 1,2,4-oxadiazole product (according to LC MS analysis) were pooled and concentrated in vacuo. The residue was dissolved in 1,4-dioxane (15 mL) and treated with 4M HCl in 1,4-dioxane (1 mL). After stirring at r. t. for 6 h, the reaction mixture was concentrated to dryness in vacuo and the residue was crystallized from isopropyl alcohol to provide analytically pure title compound. 4-[(3-Pyridin-3-yl-1,2,4-oxadiazol-5-yl) 7, 165.0, 148.7, 144.4, 138.4, 126.0, 123.9, 68.3, 59.7, 41.0, 38.8, 35.0, 32.5, 31.4, 28.4 . MS m/z 315.4 (M+H + ). 2.4.2.  4-[(3-Cyclopropyl-1,2,4-oxadiazol-5-yl) 3, 172.1, 68.7, 60.2, 41.5, 35.5, 32.9, 31.8, 28.7, 25.7, 7.8, 6.7 . MS m/z 278.5 (M+H + ). 4-[(3-(2-methoxyethyl)-1,2,4-oxadiazol-5-yl) 9, 168.0, 68.4, 68.2, 59.7, 57.8, 41.0, 38.8, 35.0, 32.3, 31.3, 28.2, 26.0, 25.2 . MS m/z 296.3 (M+H + ).
4.2.4.1.
4.
4.2.4.3.
General procedure for the preparation of compounds 4a-s.
A solution of the respective spirocyclic piperidine salt 3a-r or 12 (0.46 mmol) in CH 2 Cl 2 (5 mL) was treated with trimethylamine (n x 0.46 mmol, where n = number of salt parts per molecule)
followed by a solution of 2 (0.44 mmol) in CH 2 Cl 2 (5 mL). After a brief stirring (15 min), sodium triacetoxyboohydride (STAB, 1.32 mmol) was added and the stirring continued for 12 h at r. t. The reaction was poured into 10% aqueous NaHCO 3 (20 mL). Organic phase was separated and the aqueous phase was extracted with CH 2 Cl 2 (2 x 10 mL). The combined organic extracts were washed with brine, dried over anhydrous Na 2 SO 4 , filtered and concentrated in vacuo. The residue was fractionated on silica gel using 01% MeOH in CH 2 Cl 2 . The fractions containing the reductive amination product (according to LC MS analysis) were pooled and concentrated in vacuo. The residue was dissolved in CH 2 Cl 2 (3 mL) and treated with TFA (1 mL). The mixture was stirred at r.
t. for 18 h and concentrated in vacuo. 2M HCl in ether (3 mL) was added to the residue and the later was triturated (with occasional sonication) until a crystalline hydrochloride salt formed. The latter was separated by filtration, washed with ether and dried in vacuo to provide analytically pure compounds 4a-s.
3-[4-({4-[(4-Methyl-1-oxa-9-azaspiro[5.5]undec-9-yl)methyl]benzyl}oxy)phenyl]
propanoic acid hydrochloride (4a). 7, 156.6, 138.4, 132.7, 131.6, 129.4, 129.2, 127.7, 114.6, 68.7, 67.9, 60.2, 58.2, 51.2, 46.9, 43.9, 35.1, 34.0, 29.4, 25.4, 24.4, 22.2. HRMS (ESI) 3-[4-({4-[(4-Ethoxy-1-oxa-9 -azaspiro[5.5]undec-9yl)methyl]benzyl}oxy)phenyl]propanoic acid hydrochloride (4b).
Yield 73 7, 156.5, 138.4, 133.1, 131.6, 129.3, 129.2, 127.7, 114.5, 70.2, 68.7, 68.6, 62.1, 58.3, 58.2, 46.8, 46.6, 41.0, 35.6, 33.5, 31.9, 29.5, 28.0, 15.5 7, 156.6, 138.4, 133.1, 132.7, 131.6, 129.3, 129.2, 127.7, 114.6, 71.4, 70.1, 68.7, 58.3, 58.2, 51.2, 46.8, 46.6, 35.6, 35.1, 33.5, 31.9, 29.4, 28.1, 10.8, 2.9, 2. 8, 162.1 (d, J = 243.2 Hz), 165.5, 142.0 (d, J = 7.1 Hz), 138.5, 133.1, 131.59, 130.2 (d, J = 8.3 Hz), 129.3, 129.2, 127.8, 123.0 (d, J = 2.7 Hz), 114.6, 113.9 (d, J = 20.9 Hz), 113.7 (d, J = 21.4 Hz), 70.6, 68.7, 68.6, 68.0, 58.4, 58.3, 46.9, 46.8, 35.5, 33.5, 31.6, 30.7, 29.5, 28.3. HRMS (ESI) δ 173. 8, 156.5, 143.0, 138.5, 133.1, 131.6, 129.3, 129.2, 127.9 (q, J = 13.8 Hz), 127.8, 127.6, 125.1 (q, J = 3.8 Hz), 124.3 (q, J = 271.9 Hz), 114.5, 70.8, 68.7, 68.6, 68.0, 58.3, 58.3, 46.9, 46.8, 40.8, 35.5, 33.5, 31.6, 29.5, 28.3 HRMS (ESI) 67.8, 59.7, 58.3, 57.8, 46.8, 41.1, 35.4, 35.3, 32.3, 31.3, 29.4, 28.3, 25.9, 25.4. HRMS (ESI) 7, 156.5, 138.3, 133.0, 131.5, 129.4, 129.2, 127.7, 114.55, 68.6, 67.3, 60.1, 58.2, 46.7, 35.5, 35.1, 30.7, 30.1, 29.4, 25.3, 18. 
Molecular modeling
Protein structure source and preparation for docking
The 3D coordinates for FFA1 co-crystalized with TAK-875 were obtained from the Protein Data Bank (PDB ID: 4PHU) and used for subsequent docking procedures. 23 Protein preparation, refinement and docking was performed within Schrödinger's Maestro, version 2016-1. 24 To prepare FFA1 for docking, hydrogens and missing atoms were added, alternate residue positions were defined and the hydrogen bonding network was further optimized by re-orientating hydroxyls, amides and imidazole rings (of histidine residues) using Protein Preparation Wizard. 25
Docking protocol.
In the crystallized FFA1, four point mutations (Leu42-Ala, Phe88-Ala, Gly103-Ala, Tyr202-Phe)
were made to increase expression of the protein and to improve thermal stability. The mutant Ala88, positioned between TM3 and TM4 can be considered an important residue in stabilizing the binding conformations. 26 Therefore, this residue was mutated in silico back to Phe with extensive conformational sampling using the MacroModel Conformational Search. 27 To alleviate any strain occurring from this point mutation, a stringent two-step minimization protocol was employed, i.e. hydrogen-only minimization followed by a constrained minimization based on the X-Ray derived B-Factors, implemented with MacroModel. 27 In determining the final position of the benzyl sidechain in 4l and for selecting an appropriate docking protocol, TAK-875 was re-docked onto FFA1 and compared to the crystal structure orientation, RMSD < 2.5 Å. Furthermore, in determining a correct docking pose an appreciation of the membrane positioning was made using the Orientation of proteins in membrane (OPM) database and PPM webserver to align and perdict the position of the GPR40 receptor in a membrane. 28 Ligands were created manually in the Schrödinger Maestro 2D sketcher and prepared using LigPrep 29 to produce a low energy conformation. Receptor grid generation and docking was performed using GLIDE 30 with the extra precision (XP) algorithm while enhancing the planarity of conjugated pi groups. The centroid of the grid was defined by the center of mass of TAK-875 as positioned in the crystal structure. In all calculations the OPLS3, all atom force-field was utilized. To allow the comparison of residue positions within the GPCR family, the labels in figure 1 and figure 2 shown the Ballesteros Weinstein indexing system in subscript. 21 Images were rendered using two separate programs: maestro to represent the specific protein-ligand interactions and VMD v1.9.2 31 to visualize the membrane position and surface representations. 
Biological and ADME
Assessment of metabolic stability in mouse liver microsomes
The metabolic stability of compounds 4k-n as well as the reference compounds (Imipramine, Propranolol) was determined in liver microsomes at five time points over 40 minutes using HPLC-
MS.
Mouse hepatic microsomes were isolated from pooled (50), perfused livers of BALB/c male mice according to the standard protocol. 32 The batch of microsomes was tested for quality control using a commercial comparator preparation (Sigma-Aldrich M9441) and verapamil and propranolol as reference compounds. Microsomal incubations were carried out in 96-well plates in 5 aliquots of 40 μL each (one for each time point and dialyzing against buffer until equilibrium is achieved. Concentrations of the compounds in both plasma and buffer were determined to calculate the percentage of plasma protein bound compounds.
The assay was performed in the 96-well equilibrium dialysis apparatus (HTDialysis, LLC). Each individual well unit consisted of 2 chambers separated by a vertically aligned dialysis membrane of predetermined pore size ( . 120 μl of plasma spiked with the compound (1 μM, final solvent concentration 1%) was added to one chamber and the same aliquot of PBS buffer, pH 7.4 was added to the other chamber. After that, HTD96b dialyzer was covered with adhesive sealing film and incubated at 37°C on an orbital shaker at 100 rpm for 5 hours. An aliquot of the content of each chamber was taken and mixed with the same volume aliquot of the blank opposite matrix. In order to define non-specific loss of the compound during this assay, standard solution was created by mixing an aliquot of spiked plasma, which was incubated at 37°C without dialysis, with blank buffer. Sample of 1 μM series was diluted with 100% acetonitrile 10-fold with subsequent plasma proteins precipitation by centrifuging at 6000 rpm for 5 minutes. Incubations were performed in quadriplicates. Supernatants were analyzed using HPLC system coupled with tandem mass spectrometer. The unbound compound fraction was calculated as the peak ratio of the analyte in the buffer compartment divided by the same parameter in the corresponding plasma compartment. The following equation was used to determine the extent of plasma protein binding:
Caco-2 permeability determination
In each experiment, reference compounds Atenolol (Sigma-Aldrich, A7655), Propranolol (Sigma-Aldrich, P0884), Testosterone (Sigma-Aldrich, T1500) were tested along with the test compounds in order to assess the assay suitability. The integrity of the cell monolayer was verified by measuring the transepithelial electrical resistance (TEER) for every well using the Millicell-ERS system Ohm meter.
The concentrations of compound 4k-n in the A-B permeability assay were determined using HPLC-MS method. The LC system comprised a Shimadzu liquid chromatograph equipped with isocratic pumps (Shimadzu LC-10ADvp), an autosampler (Shimadzu SIL-HTc), a switching valve (FCV-14AH) and a degasser (Shimadzu DGU-14A). Mass spectrometric analysis was performed using an API 3000 (triple-quadrupole) instrument from AB Sciex (USA) with an electro-spray (ESI)
interface. The data acquisition and system control was performed using Analyst 1.5.2 software from AB Sciex.
The formula for calculating P app was as follows: Drug administration and sampling. For intravenous and oral administration, 4k was dissolved in 10 % β-cyclodextrin. Mice were placed into a restraining device and a bolus injection of 4k (10 mg/kg) was given via a tail vein. Oral single dose of 4k (10 mg/kg) was given by a plastic gavage. A dosing volume of 5 ml/kg was used. Mice were anesthetized by pentobarbital (0.1 ml/10 g, i.p.; Mebunat 60 mg/ml, Orion Pharma Finland) and decapitated 10, 30, 60, 120, 240 min after intravenous administration or 30, 60, 120, 240 and 360 min after oral administration (n=5 in each time point).
Blood samples were taken by a cardiac puncture using heparinized syringe and plasma was separated by centrifugation for 10 min at 2 000 g at +4°C. The plasma samples were transferred into plastic tubes and stored at −70°C until analyzed. 
